Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Limitations of current therapies
17 evidence topics · 11 sources
Summary
- Blood pressure control: In NHANES data from August 2021 to August 2023, 20.7% of US adults with hypertension had blood pressure controlled to less than 130/80 mm Hg, with no significant change from 2017 to March 2020 (22.2%). In a separate NHANES analysis, the age-adjusted proportion with controlled blood pressure declined from 53.8% in 2013 to 2014 to 43.7% in 2017 to 2018. ICER states that more than 70% of adults with hypertension remain above goal and names clinical inertia, pill burden, additive copays, variable tolerance of side effects, and low awareness as contributors.
- Underuse of aldosterone-targeted therapy: Among NHANES adults with apparent treatment-resistant hypertension, 8.3% were taking a mineralocorticoid receptor antagonist, rising from 6.3% in 2003 to 2004 to 13.3% in 2017 to 2020. Among US Veterans with apparent treatment-resistant hypertension, 4,277 (1.6%) were tested for primary aldosteronism, and testing was associated with a 4-fold higher likelihood of starting a mineralocorticoid receptor antagonist (hazard ratio 4.10).
- Tolerability of fourth-line options: The 2025 AHA/ACC guideline states that 4% to 40% of adults with resistant hypertension cannot tolerate spironolactone because of hyperkalemia or antiandrogenic side effects, and that randomized trials have not demonstrated a reduction in home or 24-hour blood pressure with eplerenone at 25 to 100 mg daily compared with placebo. ICER reports gynecomastia rates of 3.9% to 6% with spironolactone in observational hypertension studies. Patient groups told ICER that clinicians are often reluctant to start spironolactone because of potential side effects. With baxdrostat, hyperkalemia led to discontinuation in 5.7% of participants in the BaxHTN long-term extension (safety data to 54 weeks), and serum potassium above 6 mmol/L occurred in 9.5% of the pooled baxdrostat arm and 0.8% of the placebo arm. Edema or fluid retention occurred in 9% of participants receiving aprocitentan at the approved 12.5 mg dose and 2% receiving placebo. ICER describes beta-blockers, alpha blockers, and central sympatholytic drugs as less efficacious and less well tolerated, and the guideline reserves renal denervation for adults with intolerable side effects to optimal drug regimens.
- Adherence and discontinuation: The weighted national nonadherence rate among 23.8 million adults with hypertension who filled antihypertensive prescriptions was 31.0%. A meta-analysis of 24 studies in apparent treatment-resistant hypertension estimated a pooled nonadherence prevalence of 31.2% (range 3.3% to 86.1%). Among Medicare beneficiaries starting antihypertensive treatment, discontinuation was 21.0% in 2007 and 21.3% in 2012, and low adherence fell from 37.4% in 2007 to 31.7% in 2012.
- Therapeutic inertia and access: ICER reports hearing that it often takes three to six months to adjust or add a medication in people with uncontrolled hypertension, and patients described readings above 140 mm Hg that were not acted on. The guideline links clinical inertia, among other factors, to the higher frequency of resistant hypertension in Black populations. Patients told ICER that prior authorization and step therapy can lead people to abandon treatment.
Blood pressure control: NHANES August 2021 to August 2023
Blood pressure control: trends from 1999 to 2018
“the age-adjusted estimated proportion with controlled blood pressure increased from 31.8% in 1999-2000 to 48.5% in 2007-2008, remained stable through 2013-2014 (53.8%), and then declined to 43.7% in 2017-2018.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Blood pressure control and barriers to treatment: ICER assessment
Underuse of mineralocorticoid receptor antagonists in apparent treatment-resistant hypertension
“Among those with aTRH, 84.3% were on ACE inhibitors/ARBs, 72.1% on thiazide diuretics, 55.4% on calcium channel blockers, 32.3% on a loop diuretic and 8.3% on mineralocorticoid receptor antagonists (MRA).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among adults with aTRH, utilization of MRAs increased over time from 6.3% in 2003–2004 to 13.3% in 2017–2020.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“less than 1 in 5 adults with aTRH were prescribed an MRA despite high quality evidence supporting its use.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Limited adaption could be related to the above issues or concerns specific to MRA use such as hyperkalemia, the need for routine monitoring of labs or concerns about renal dysfunction.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Underuse of aldosterone-targeted therapy: lorundrostat phase 3 trial report
“However, aldosterone-targeted antihypertensive medication is underused worldwide in the treatment of hypertension.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, MRAs are underused due to safety concerns with hyperkalemia and, in the case of spironolactone, chemotype-specific androgenic effects.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Primary aldosteronism testing and mineralocorticoid receptor antagonist initiation
“4277 (1.6%) patients who were tested for primary aldosteronism were identified.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Testing was associated with a 4-fold higher likelihood of initiating MRA therapy (HR, 4.10 [CI, 3.68 to 4.55]) and with better BP control over time.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Spironolactone and eplerenone intolerance and efficacy: guideline
Hyperkalemia and gynecomastia with mineralocorticoid receptor antagonists
Clinician reluctance to start spironolactone: patient and clinician input to ICER
Aldosterone synthase inhibitors: hyperkalemia with baxdrostat
Other fourth-line and add-on options: efficacy and tolerability
Medication nonadherence: insured US adults, 2015
“We included 23.8 million hypertensive adults who filled 265.8 million prescriptions for antihypertensive medications.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The overall weighted national nonadherence rate was 31.0%, with greater nonadherence among women versus men, younger versus older adults (aged 18-34 years, 58.1%; aged 65-74 years, 24.4%), fixed-dose combination medication nonusers (31.2%) versus users (29.4%), and by pharmacy outlet type (retail only, 30.7%; any mail order, 19.8%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Medication nonadherence: apparent treatment-resistant hypertension
“From an initial discovery of 921 studies, we identified 24 studies that measured medication adherence for patients with uncontrolled BP despite being prescribed three or more antihypertensive medications of different classes.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“By using a random effects model, the pooled prevalence of nonadherence was 31.2%” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“with nonadherence rates ranging from 3.3 to 86.1%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Discontinuation and low adherence after treatment initiation: Medicare beneficiaries
“Between 2007 and 2012, 41,135 Medicare beneficiaries in the 5% sample initiated antihypertensive medication.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Discontinuation was stable over the study period (21.0% in 2007 and 21.3% in 2012; p-trend=0.451).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Low adherence decreased from 37.4% in 2007 to 31.7% in 2012 (p-trend<0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote